Tysabri®

Random entry RSS

Posted in:
Legal

RFEM’s Biosimilars Inter Partes Review (IPR) Dashboard
By C. Nichole Gifford and Benjamin R. Holt November 14, 2018 Comments are off
RFEM’s Biosimilars IPR Dashboard provides current information on IPR proceedings related to proposed biosimilar...

Read more

Tagged with: abatacept, adalimumab, Avastin®, bevacizumab, Enbrel®, etanercept, Featured, Herceptin®, Humira®, IPR, Legal, Natalizumab, Neulasta®, News, Orencia®, pegfilgrastim, PTAB, Rituxan®, Rituximab, trastuzumab, Tysabri®, USPTO

http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
ShareEmail, Linked In, Twitter, Facebook, Google Plus

Back to Top